Meeting
2023 ASCO Annual Meeting
Population pharmacokinetic-pharmacodynamic model of nirogacestat effects on B-cell maturation antigen in healthy subjects.
Authors
Todd Shearer
SpringWorks Therapeutics, Inc., Stamford, CT
Todd Shearer , Rex L. Williams Jr., Mark Johnson , Ewa Cendrowicz , Cathrine Leonowens , Margaret Smith , Todd Baughman , Caroline J. Breitbach , L. Mary Smith , Shinta Cheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8027)
DOI
10.1200/JCO.2023.41.16_suppl.8027
Abstract #
8027
Poster Bd #
19
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.
First Author: Suzette Girgis
Poster
2023 ASCO Annual Meeting
Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1.
First Author: Xuewen Ma
Poster
2023 ASCO Annual Meeting
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.
First Author: Kristoffer Staal Rohrberg
Poster
2023 ASCO Annual Meeting
Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies.
First Author: A. Dimitrios Dimitrios Colevas